Sort
30,917 grants matching “tumor microenvironment”
IL-15 and -21 armored GPC3-specific CAR T cells for children with solid tumors
$622,304Andras A. Heczey · Baylor College Of Medicine · R01 · FY2023 · CA
Mayo Clinic SPORE in Ovarian Cancer
$622,294Scott H Kaufmann · Mayo Clinic Rochester · P50 · FY2014 · CA
Interrogating the role of arachidonic acid metabolism in modulating the tumor immune microenvironment as a novel path to therapeutic intervention
$622,227Timothy J Yeatman · University Of South Florida · U01 · FY2025 · CA
Towards Translation of MU-CN29: New Therapeutic Nanoparticle for Drug-Resistant NSCLC
$622,068Raghuraman Kannan · University Of Missouri-Columbia · R01 · FY2022 · CA
Tailoring CAR T cell therapy for Hodgkin Lymphoma
$622,000Barbara Savoldo · Univ Of North Carolina Chapel Hill · R01 · FY2022 · CA
IDENTIFICATION AND THERAPEUTIC TARGETING OF PARACRINE SENESCENCE FACTORS IN THE PROSTATE TUMOR MICROENVIRONMENT
$621,918Fred Hutchinson Cancer Research Center · · FY2008 · Department of Defense
Viral oncoprotein targeted immune therapy for Merkel cell carcinoma
$621,892Paul Nghiem · University Of Washington · R01 · FY2014 · CA
preclinical optimization of BCMA directed T cell therapy
$621,878Marta Chesi · Mayo Clinic Arizona · R01 · FY2025 · CA
preclinical optimization of BCMA directed T cell therapy
$621,878Marta Chesi · Mayo Clinic Arizona · R01 · FY2023 · CA
Glycosylation and Immune Evasion in Urologic Tumors
$621,878Sharon Pitteri · Stanford University · U01 · FY2019 · CA
Dissect governing factors for tumor stem cell dormancy in biomimetic vascular/GBM model
$621,861Hongyan Jenny Zou · Icahn School Of Medicine At Mount Sinai · R01 · FY2020 · NS
Preclinical Testing of Targeted Therapies for Neurofibromas
$621,744David W. Clapp · Indiana University Indianapolis · U01 · FY2010 · NS
Preclinical Testing of Targeted Therapies for Neurofibromas
$621,744David W. Clapp · Indiana University Indianapolis · U01 · FY2010 · NS
(PQD5) Avatar-directed Treatment for Ovarian Cancer
$621,606Paul Haluska · Mayo Clinic Rochester · R01 · FY2014 · CA
Ovarian Cancer Epigenetics, Immunity and Therapy
$621,601Weiping Zou · University Of Michigan At Ann Arbor · R01 · FY2018 · CA
Ovarian Cancer Epigenetics, Immunity and Therapy
$621,601Weiping Zou · University Of Michigan At Ann Arbor · R01 · FY2020 · CA
Role of Cancer-Associated Fibroblasts in Cholangiocarcinoma
$621,575Robert F. Schwabe · Columbia University Health Sciences · R01 · FY2021 · CA
A single-arm phase II study to evaluate the safety and efficacy of combination systematic chemotherapy and multiple rounds of endoscopic ultrasound-guided radiofrequency ablation in pancreatic cancer
$621,551Nirav Thosani · University Of Texas Hlth Sci Ctr Houston · R01 · FY2024 · CA
Combating melanoma with an attenuated bacterial therapeutic
$621,545Jianxun Jim Song · Texas A&M University Health Science Ctr · R01 · FY2023 · CA
Novel Methods of Chemo-sensitizing Low-proliferative Disseminated Tumor Cells in Triple Negative Breast Cancer
$621,513David D Tran · University Of Southern California · R01 · FY2023 · CA
Role of Cancer-Associated Fibroblasts in Cholangiocarcinoma
$621,461Robert F. Schwabe · Columbia University Health Sciences · R01 · FY2020 · CA
Notch ligands as oncogenic drivers and therapeutic targets in T-cell lymphomas
$621,443Ryan A Wilcox · University Of Michigan At Ann Arbor · R01 · FY2025 · CA
(PQ#3) Novel tumor intrinsic PD-L1 signals direct tumor immune cell infiltration
$621,419Tyler J. Curiel · University Of Texas Hlth Science Center · R01 · FY2019 · CA
Project 1: Physical modeling and dynamics of tumor cell migration mechanics
$621,264David J Odde · University Of Minnesota · U54 · FY2018 · CA
Chemoimmunoprevention of EGFR-Driven Non-Small Cell Lung Cancer
$621,239Ming You · Medical College Of Wisconsin · R01 · FY2019 · CA